Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for medical industry professionals · Wednesday, May 23, 2018 · 448,332,423 Articles · 3+ Million Readers

PLA Pharmaceuticals Market Analysis 2017 (By Segment, Key Players and Applications) and Forecasts

Partnerships, Licensing, Investments and M&A Deals and Trends for January 2017 in Pharmaceuticals

PUNE, INDIA, October 30, 2017 / -- Summary
Partnerships, Licensing, Investments and M&A Deals and Trends for January 2017 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in January 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.


- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy
- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Content: Key Points
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 6
2 Pharmaceuticals & Healthcare, Global, Deal Summary 10
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, January 2017 10
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, January 2017 12
2.2.1 Johnson & Johnson to Acquire Actelion for USD30 Billion 12
2.2.2 Takeda Pharma Acquires Ariad Pharma for up to USD5.2 Billion in Tender Offer 13
2.2.3 Les Laboratoires Servier Enters into Licensing Agreement with Pieris Pharma 13
2.2.4 Biogen to Enter into Licensing Agreement with Forward Pharma 14
2.2.5 Ipsen to Acquire Oncology Assets from Merrimack Pharma 15
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, January 2017 17
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, January 2017 18
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 19
3.1 Pharmaceuticals & Healthcare, Global, M&A, January 2017 19
3.1.1 Top M&A Deals in January 2017 20
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, August 2016 - January 2017 21
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, January 2017 22
3.2.1 Top Equity Offering Deals in January 2017 23
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, August 2016 - January 2017 23
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, January 2017 25
3.3.1 Top PE/VC Deals in January 2017 26
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, January 2017 27


Get in touch:

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here

Powered by EIN Presswire